|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:subsidiary
|
|
gptkbp:acquiredBy
|
gptkb:Sanofi
|
|
gptkbp:acquisitionYear
|
2011
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:focusesOn
|
immunology
oncology
multiple sclerosis
rare diseases
|
|
gptkbp:formerName
|
gptkb:Genzyme_Corporation
|
|
gptkbp:founded
|
1981
|
|
gptkbp:founder
|
gptkb:Sheridan_Snyder
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi Genzyme
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:David_Meeker
gptkb:Sheridan_Snyder
Bill Sibold
|
|
gptkbp:location
|
gptkb:Cambridge
|
|
gptkbp:notableAchievement
|
major contributor to Gaucher disease therapy
pioneer in rare disease treatments
|
|
gptkbp:notableProduct
|
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Myozyme
gptkb:Renagel
gptkb:Thymoglobulin
gptkb:Aubagio
gptkb:Lemtrada
|
|
gptkbp:numberOfEmployees
|
~10,000 (before acquisition)
|
|
gptkbp:parentCompany
|
gptkb:Sanofi
|
|
gptkbp:publiclyTraded
|
No
|
|
gptkbp:servesArea
|
Worldwide
|
|
gptkbp:specializesIn
|
orphan drugs
enzyme replacement therapies
|
|
gptkbp:stockExchange
|
formerly NASDAQ (GENZ)
|
|
gptkbp:type
|
gptkb:subsidiary
|
|
gptkbp:website
|
https://www.sanofigenzyme.com/
|
|
gptkbp:bfsParent
|
gptkb:Aldurazyme
gptkb:Cerezyme
gptkb:Fabrazyme
gptkb:Myozyme
gptkb:Cerdelga
gptkb:Caprelsa
gptkb:Route_128_corridor
gptkb:Lemtrada
|
|
gptkbp:bfsLayer
|
7
|